Health News
How Pesticides May Heighten Heart Risks
In the 1970s, the pesticide DDT was banned in the US and many other countries. Its effects, however, may linger on. To this day, pesticide exposure may increase heart health risks.
Heart Attack During Exercise: Not a Big Threat
Heart attacks can strike with no warning, even while exercising. However, middle-aged adults shouldn't be afraid to exercise, as the likelihood of sudden heart attacks may be low during vigorous activity.
Blood Pressure After Heart Problems: New Treatment Guidelines
Keeping blood pressure in check is important for avoiding a heart attack — especially if you've already survived one. New guidelines could help doctors and patients keep blood pressure on track after heart problems.
How to Talk with Your Doctor About Statins
Heads or tails? Chocolate or vanilla? Life is full of decisions — even for doctors. A good discussion allows patients to share in the decision-making process for their health care.
It's Something in the Air: Pollution and Health
You've got to breathe to live, but breathing polluted air could put you at risk of health problems.
FDA Approves Blood Pump System
The U.S. Food and Drug Administration today approved the Impella 2.5 System, a miniature blood pump system intended to help certain patients maintain stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI) procedures.
Parents Smoking Might Be Heartbreaker for Kids
Many parents may try to step away from their children when they smoke, but children exposed to even small amounts of smoke may grow up to have heart problems.
How Having Life Purpose Might Help Your Brain
Finding your purpose in life may give you more than just a sense of fulfillment — it may also give you better brain health.
DOD Study Supports Benefit-Risk Profile of Pradaxa for AFib
Ridgefield, CT, November 17, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System database showing that non-valvular atrial fibrillation (NVAF) patients treated with Pradaxa® (dabigatran etexilate mesylate) in routine clinical care experienced reduced rates of stroke, major bleeding, death and other types of bleeding, along with increased lower gastrointestinal (GI) bleeding, compared to patients treated with warfarin.
Lilly Provides Update on Evacetrapib Phase 3 Trial
INDIANAPOLIS, Feb. 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months.